(RTTNews.com) – Bio-pharmaceutical company Horizon Pharma plc Friday said it would acquire Crealta Holdings LLC for $510 million in cash, expanding its Orphan business, with the addition of KRYSTEXXA, the first and only FDA-approved medicine for chronic refractory gout.
The deal is expected to add $70 million – $80 million in net sales and $45 million – $50 million in adjusted EBITDA for Horizon, in the first twelve months, upon completion.
The acquisition, which is likely to close in the first quarter 2016 and approved by the boards of both companies, is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approval in the United States.
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.